Sanofi India Ltd
Company Profile
Business description
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
1,285
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
stocks
We remove our Moat Rating from ASX listed share
stocks
Best sustainable companies to own in 2026
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 78.80 | -0.87% |
| CAC 40 | 8,237.78 | 26.28 | 0.32% |
| DAX 40 | 24,936.33 | 67.64 | 0.27% |
| Dow JONES (US) | 49,142.94 | 165.76 | 0.34% |
| FTSE 100 | 10,122.57 | 118.00 | 1.18% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,504.05 | 108.23 | 0.46% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,929.87 | 27.82 | 0.40% |
| S&P/ASX 200 | 8,682.80 | 88.50 | -1.01% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |